vidarabine has been researched along with Thrombotic Microangiopathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Citrin, DE; Rosenberg, SA; Tseng, J; Waldman, M; White, DE; Yang, JC | 1 |
| Forman, SJ; Karanes, C; Kogut, N; Krishnan, AY; Nademanee, A; Nakamura, R; O'Donnell, M; Palmer, JM; Parker, P; Pullarkat, V; Rodriguez, R; Rosenthal, J; Senitzer, D; Shayani, S; Smith, E; Snyder, D | 1 |
2 trial(s) available for vidarabine and Thrombotic Microangiopathies
| Article | Year |
|---|---|
Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Immunotherapy, Adoptive; Interleukin-2; Lymphocytes, Tumor-Infiltrating; Male; Melanoma; Middle Aged; Pilot Projects; Radiation Injuries; Recombinant Proteins; Thrombotic Microangiopathies; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2014 |
A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.
Topics: Adolescent; Adult; Busulfan; Child; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Pilot Projects; Radiation Dosage; Siblings; Sirolimus; Survival Analysis; Tacrolimus; Thrombotic Microangiopathies; Tissue Donors; Transplantation Conditioning; Vidarabine; Young Adult | 2010 |